...
首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Prevalence of anti-S100A10 antibodies in antiphospholipid syndrome patients
【24h】

Prevalence of anti-S100A10 antibodies in antiphospholipid syndrome patients

机译:抗磷脂综合征患者抗S100A10抗体的患病率

获取原文
获取原文并翻译 | 示例

摘要

Introduction: Annexin A2 (ANXA2), an endothelial cell receptor for plasminogen and tissue plasminogen activator, has been identified as a new autoantigen in antiphospholipid syndrome (APS). ANXA2 can exist as a monomer or a heterotetrameric complex with S100A10 protein. This S100A10 subunit also plays a pivotal role in the regulation of fibrinolysis. The aim of this study was to evaluate the prevalence of autoantibodies directed against S100A10 protein in patients with APS.
机译:介绍:膜蛋白A2(ANXA2)是纤溶酶原和组织纤溶酶原激活剂的内皮细胞受体,已被鉴定为抗磷脂综合征(APS)中的一种新的自身抗原。 ANXA2可以作为单体或异淀粉与S100A10蛋白存在。 该S100A10亚基在纤维蛋白溶解的调节中也起到了枢轴作用。 本研究的目的是评估针对AP患者针对S100A10蛋白的自身抗体的患病率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号